IndustryCompany release

Psyence Biomedical adds ibogaine for opioid use disorder via new Texas subsidiary

Psyence Biomedical Ltd. (PBM) · Thu 19 Nov 2026

The psychedelic drug developer reports a six-month net loss of $1.94M and cash of $21.1M, while its psilocybin Phase IIb trial continues in Australia.

Psyence Biomedical has set up Texas Ibogaine Research Corporation and signed a binding term sheet for a U.S. licence to PsyLabs' ibogaine hydrochloride, with opioid use disorder as the target indication. The move was disclosed in the company's management discussion and analysis (MD&A) for the six months to 30 September 2026, dated 19 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Psyence Biomedical Ltd. ↗

Article written by VigiEye from the official source (Psyence Biomedical Ltd.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →